Back

Reduction of LDL and Lp (a) under the PCSK9 inhibitor Evolocumab/Alirozumab in patients with familial hypercholesterolemia or manifest atherosclerosis

6 April 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session II - Friday 08:30 - 18:00 - Diabetes/ Lipids/Obesity/Nutrition_Part 2 Lipids EAPC Premium Access EuroPrevent 2017

About the speaker

Photo
Mr Madan Raj Poudel

University Clinic OWL, Bielefeld (Germany)

12 More presentations in this session

Presentation thumbnail
Diabetes/ Lipids/Obesity/Nutrition_Part 2 - Poster discussant:.
Presentation thumbnail
Atrial fibrillation preventive effect of n-3 polyunsaturated fatty acids in patients with hypertension
Doctor S. Okamoto (Tsu, JP)
Abstract
Presentation thumbnail
High rate of achievement of target values in LDL-cholesterol reduction through cardiac rehabilitation in patients with acute coronary syndrome
Professor B. Schwaab (Timmendorfer Strand, DE)
Abstract
Presentation thumbnail
Predictors of non-coronary aterosclerosis progression one year after coronary surgery
Professor O. Barbarash (Krasnodar, RU)
Abstract
Presentation thumbnail
Benefit of the PCSK9 inhibitor evolocumab in patients undergoing lipid apheresis

Access the full session

Session thumbnail
Poster Session II - Friday 08:30 - 18:00 - Diabetes/ Lipids/Obesity/Nutrition_Part 2

The Event

Event poster

EuroPrevent 2017

6 April - 8 April 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources